e-Pharmatimes

With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabhalta, AstraZeneca has answered in the United States for its add-on oral treatment in the indication. The FDA has signed off on Voydeya (danicopan), a factor D inhibitor, to treat PNH patients with extravascular hemolysis (EVH), a condition that causes red blood cell destruction outside of the blood vessels. The nod comes three months after the Japanese Ministry of Health, Labour and Welfare (JHLW) became the first regulator worldwide to endorse the therapy. Voydeya works as an add-on for AZ’s pair of PNH standard-of-care blockbusters—Soliris, which has been on the market for 17 years and generated $3.2 billion in sales in 2023, and its follow-on Ultomiris, which was approved in 2018 and accounted for $3 billion in sales last year. AZ said that 10% to 20% of those who use C5 inhibitors such as

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Invalidating a patent is a complex process that involves considering various legal standards and criteria. When it comes to patent invalidations, there are certain standards that courts in Europe and the United States adhere to.  In Europe, the primary legal standard applied in patent invalidations is the "European Patent Convention" (EPC), which governs the grant and enforcement of patents. Under the EPC, a patent can be invalidated if it does not meet the criteria of novelty, inventive step, and industrial applicability. The courts in Europe assess the patent by examining prior art, determining whether the claimed invention is new, non-obvious, and capable of industrial application. Additionally, the European courts also consider validity requirements such as sufficiency of disclosure, clarity, and added matter. In the United States, patent invalidation proceedings are conducted by the US Patent and Trademark Office (USPTO) through the "inter partes review" (IPR)

Patent prosecution in Jordan involves a series of steps to obtain patent protection for an invention within the country.  Here's an overview: 1. Patent Search:  Begin by conducting a patent search to ensure your invention is novel and not already patented in Jordan. This can be done through the Jordanian Patent Office (JPO) or online databases. 2.Draft a Patent Application:  Prepare a detailed patent application describing your invention's technical aspects, including drawings and claims. It's advisable to seek legal counsel or a patent attorney experienced in Jordanian patent law for assistance. 3.Filing the Application:  Submit your patent application to the JPO. Ensure it complies with the required format and includes all necessary documentation. Pay the filing fees. 4. Examination:  The JPO will examine your application to determine its patentability. This process may involve correspondence and amendments to the application if required. 5. Publication:  Once the JPO ap

Patent litigation in Singapore. The process involves several steps: 1. Filing a Writ of Summons: The plaintiff initiates the litigation by filing a Writ of Summons, outlining their claims and relief sought. This officially starts the lawsuit. 2.Serving Court Documents:  The plaintiff serves the court documents to the defendant, who responds by filing a Memorandum of Appearance to indicate their participation in the case. 3.Pleadings and Statements of Case:  Both parties exchange their statements of case, including the Statement of Claim by the plaintiff and the Statement of Defence by the defendant. Further statements and counterclaims might also be filed. 4.Case Management Conference (CMC):  The court schedules a CMC to manage the case's progress, including issues like discovery, evidence, and trial dates. 5.Discovery:  Each party gathers and discloses relevant documents and evidence that will be used during the trial. This can include expert reports, technical documents, and comm

Armenia Pharmaceutical patent litigation. Pharmaceutical patent litigation in Armenia typically follows a legal process similar to that of other countries. Here's a general outline of the steps involved: 1.Identification of Patent Infringement:  The patent holder identifies a potential infringement of their patent rights by a generic drug manufacturer. 2.Cease and Desist Letter:  The patent holder may send a cease and desist letter to the alleged infringer, requesting them to stop manufacturing, selling, or marketing the allegedly infringing generic drug. 3.Legal Action Initiation:  If the dispute is not resolved through negotiation, the patent holder may initiate legal action by filing a lawsuit against the alleged infringer in the appropriate court. This may be the Intellectual Property Court or another relevant court. 4.Defendant's Response:  The defendant, in this case, the generic drug manufacturer, responds to the lawsuit by presenting their arguments and evidence. 5. Evi